Therapeutic Drug Monitoring to Spike to $2.69 Billion by 2019

Therapeutic Drug Monitoring to Spike to $2.69 Billion by 2019

ID: 240438

(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 03/18/13 -- TriMarkPublications.com cites in its newly published "" report that (TDM) will spike to $2.69 billion by 2019. For more information, visit: .

can be categorized into seven main modalities: antiepileptics, antiarrhythmics, antibiotics, antineoplastics, bronchodilators, immunosuppressives and HIV/AIDS drugs. The global market is dominated by eight major suppliers that account for a combined 88.3% of the global market. The U.S. market is expected to grow to $1.84 billion by 2019 at a CAGR of 12.6%.

The "" report covers:

Chemiluminescence

High Pressure Liquid Chromatography (HPLC)

Gas Chromatography/Mass Spectrometry

Liquid Chromatography/Mass Spectrometry

Flucytosine

Triazoles

Itraconazole

Voriconazole

Posaconazole

Enzyme Immunoassays

Enzyme Multiplied Immunoassay Technique

Cloned Enzyme Donor Immunoassays

Radio Immunoassays

Fluorescence Polarization Immunoassays

Lateral Flow Immunoassays

Particle Enhanced Turbidimetric Inhibition Immunoassays

Affinity Chrome Mediated Immunoassays

The "" report examines companies manufacturing equipment and supplies in the world. Companies covered include: Abaxis, Abbott, Alere, Alfa Wassermann, AMS, Beckman Coulter, BioMerieux, Carolina Chemistries, DiaSorin, Grifols, Horiba, Medica, Nova Biomedical, Ortho Clinical Diagnostics, Polymedico, Randox, Roche and Siemens.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit: .



TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit .



The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.









TriMarkPublications.com
Media Relations
1-888-OK-TRIMARK

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Fortress Real Capital Investors in Flato's Markham Project Exit Early Resource Capital Corp. Declares Quarterly Cash Dividends for Preferred Stock
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 18.03.2013 - 17:30 Uhr
Sprache: Deutsch
News-ID 240438
Anzahl Zeichen: 0

contact information:
Town:

NEW YORK, NY



Kategorie:

Commercial & Investment Banking



Diese Pressemitteilung wurde bisher 211 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Therapeutic Drug Monitoring to Spike to $2.69 Billion by 2019"
steht unter der journalistisch-redaktionellen Verantwortung von

TriMarkPublications.com (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von TriMarkPublications.com



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z